Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aripiprazole versus other second-generation antipsychotics for smoking cessation in hospitalized patients with manic bipolar I disorder
IRCT20181026041468N1Phase 4Completed
- Sponsor
- Arak University of Medical Sciences
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-blind trial of aripiprazole, risperidone, olanzapine and quetiapine in nicotine dependence and bipolar I disorder (2 arms), sponsored by Arak University of Medical Sciences. Primary endpoint: Nicotine dependency. Started Sep 2019; status: completed.
02
Drugs
aripiprazolerisperidoneolanzapinequetiapine
03
Conditions
nicotine dependencebipolar I disorder
Beyond the preview
Go deeper on IRCT20181026041468N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20181026041468N1.